<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR150">
 <label>150.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gou</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Zheng</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Peng</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Men</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Zheng</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Zeng</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Guo</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Luo</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Wei</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Qian</surname>
    <given-names>Z</given-names>
   </name>
  </person-group>
  <article-title>Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro</article-title>
  <source>Int J Pharm</source>
  <year>2009</year>
  <volume>375</volume>
  <issue>1-2</issue>
  <fpage>170</fpage>
  <lpage>176</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ijpharm.2009.04.007</pub-id>
  <?supplied-pmid 19427143?>
  <pub-id pub-id-type="pmid">19427143</pub-id>
 </element-citation>
</ref>
